Target intelligence / Profile preview

RNA, U6 small nuclear 262, pseudogene (RNU6-262P)

Target
RNU6-262P
Molecular classification
Pseudogene, Small nuclear RNA (snRNA) pseudogene
01

Overview

RNU6-262P is a pseudogene of the U6 small nuclear RNA (snRNA) gene family. Unlike canonical U6 snRNAs, which are essential for the spliceosome-mediated splicing of pre-mRNA, pseudogenes such as RNU6-262P are nonfunctional genomic elements generated through retrotransposition events, often involving LINE elements[4]. U6 snRNAs are highly conserved and function as part of the catalytic core of the spliceosome, but pseudogenes (like RNU6-262P) lack the necessary regulatory sequences or structural integrity to produce functional RNA products[1][4]. U6 snRNA pseudogenes can serve as markers of retrotransposition activity in the genome but are not known to have direct biological functions, disease associations, or therapeutic relevance[4]. There is no evidence that RNU6-262P is a protein, functional enzyme, receptor, or that it modulates any signaling, metabolic, or pathological process[4]. Pseudogenes in general may occasionally impact gene regulation (e.g., acting as competitive endogenous RNAs), but there is no direct evidence that RNU6-262P fulfills such a role[2]. Key context: RNU6-262P is a pseudogene, not an active molecular target, therapeutic target, or biomarker. Its presence in the genome reflects the history of retrotransposition events rather than biological activity[4]. There are no known drugs, mechanisms of action, or diseases associated with RNU6-262P. It should not be listed as a canonical molecular target in drug discovery or biomedical contexts. Errors/Concerns: This entry is not a misspelling, but it does not correspond to an active molecular target. Use is_target: false for structured curation. If a canonical functional form is needed, then U6 small nuclear RNA (RNU6-2) would be the active (non-pseudogene) form[3]. Summary for database structuring: This entry represents a nonfunctional RNA pseudogene; it should not be regarded as a molecular therapeutic target or a receptor/enzyme/transporter.

Other names
RNU6-262PU6 snRNA pseudogene 262U6 pseudogene 262

Beyond the preview

Go deeper on RNA, U6 small nuclear 262, pseudogene (RNU6-262P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, U6 small nuclear 262, pseudogene (RNU6-262P).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call